Deerfield Management Company L.P. Series C Boosts Stake in Omnicell, Inc. (NASDAQ:OMCL)

Deerfield Management Company L.P. Series C boosted its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 238.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,474 shares of the company's stock after acquiring an additional 22,174 shares during the period. Deerfield Management Company L.P. Series C owned 0.07% of Omnicell worth $852,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Omnicell by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company's stock valued at $165,200,000 after acquiring an additional 80,312 shares in the last quarter. Pacer Advisors Inc. grew its position in Omnicell by 32.6% during the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company's stock valued at $56,047,000 after purchasing an additional 508,789 shares during the last quarter. Champlain Investment Partners LLC grew its position in Omnicell by 16.0% during the 1st quarter. Champlain Investment Partners LLC now owns 1,753,205 shares of the company's stock valued at $51,246,000 after purchasing an additional 241,235 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Omnicell by 0.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company's stock valued at $31,955,000 after purchasing an additional 3,570 shares in the last quarter. Finally, Federated Hermes Inc. raised its holdings in Omnicell by 1,113.6% in the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company's stock worth $26,830,000 after buying an additional 909,480 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on OMCL. Wells Fargo & Company boosted their price objective on shares of Omnicell from $26.00 to $30.00 and gave the stock an "equal weight" rating in a report on Friday, August 2nd. JPMorgan Chase & Co. boosted their price target on Omnicell from $26.00 to $37.00 and gave the stock a "neutral" rating in a research note on Friday, August 23rd. Barclays raised Omnicell from an "underweight" rating to an "equal weight" rating and increased their price objective for the company from $26.00 to $39.00 in a research report on Friday, August 2nd. StockNews.com lowered Omnicell from a "buy" rating to a "hold" rating in a research report on Thursday, September 19th. Finally, Bank of America raised their price target on shares of Omnicell from $34.00 to $44.00 and gave the company a "buy" rating in a report on Friday, August 2nd. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Omnicell presently has a consensus rating of "Hold" and an average price target of $37.83.

Omnicell Stock Performance

Shares of NASDAQ OMCL traded up $0.69 during midday trading on Friday, hitting $43.02. 336,612 shares of the company's stock traded hands, compared to its average volume of 534,726. The firm has a fifty day moving average of $40.44 and a 200 day moving average of $32.66. The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of -94.02, a price-to-earnings-growth ratio of 48.57 and a beta of 0.83. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $46.47. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.37. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The company had revenue of $276.80 million for the quarter, compared to analysts' expectations of $254.41 million. During the same period last year, the firm earned $0.29 EPS. Omnicell's revenue for the quarter was down 7.4% compared to the same quarter last year. On average, analysts forecast that Omnicell, Inc. will post 0.64 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.